Abstract:Understanding the role of N6-adenosine methylation (m6A) in the tumor microenvironment (TME) is important since it can contribute to tumor development. However, the research investigating the association between m6A and TME and cervical cancer is still in its early stages. The aim of this study was to discover the possible relationship between m6A RNA methylation regulators, TME, PD-L1 expression levels, and immune infiltration in cervical cancer. We gathered RNA-seq transcriptome data and clinical information from cervical cancer patients using The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases. To begin, researchers assessed the differences in m6A regulatory factor expression levels between cervical cancer and normal tissues. Clustering analysis was adapted to assess PD-L1 expression, immunological score, immune cell infiltration, TME, and probable pathways in cervical cancer samples. The majority of m6A regulators were found to be considerably overexpressed in cervical cancer tissues. Using consensus clustering of 21 m6A regulators, we identified two subtypes (clusters 1/2) of cervical cancer, and we found that WHO stage and grade were associated with the subtypes. PD-L1 expression increased dramatically in cervical cancer tissues and was significantly linked to ALKBH5, FTO, METTL3, RBM15B, YTHDF1, YTHDF3, and ZC3H13 expression levels. Plasma cells and regulatory T cells (Tregs) were considerably elevated in cluster 2. Cluster 1 is involved in numerous signature pathways, including basal transcription factors, cell cycle, RNA degradation, and the spliceosome. The prognostic signature-based riskscore (METTL16, YTHDF1, and ZC3H13) was found to be an independent prognostic indicator of cervical cancer. The tumor immune microenvironment (TIME) was linked to m6A methylation regulators, and changes in their copy number will affect the quantity of tumor-infiltrating immune cells dynamically. Overall, our research discovered a powerful predictive signature based on m6A RNA methylation regulators. This signature correctly predicted the prognosis of cervical cancer patients. The m6A methylation regulator could be a critical mediator of PD-L1 expression and immune cell infiltration, and it could have a significant impact on the TIME of cervical cancer.

Gene signatures, immune infiltration, and drug sensitivity based on a comprehensive analysis of m6a RNA methylation regulators in cervical cancer

Single-cell N6-methyladenosine Regulator Patterns Guide Intercellular Communication of Tumor Microenvironment That Contribute to Colorectal Cancer Progression and Immunotherapy

The Methylation Modification of M6a Regulators Contributes to the Prognosis of Head and Neck Squamous Cell Carcinoma

Molecular Characterization and Clinical Relevance of m6A RNA Methylation Regulators in Cervical Cancer

M6a Regulator-Mediated Tumour Infiltration and Methylation Modification in Cervical Cancer Microenvironment

Comprehensive characterization of tumor microenvironment and m6A RNA methylation regulators and its effects on PD-L1 and immune infiltrates in cervical cancer

Gene signature of m6A RNA regulators in diagnosis, prognosis, treatment, and immune microenvironment for cervical cancer

The Emerging Molecular Mechanism of M6a Modulators in Tumorigenesis and Cancer Progression

N6-methyladenosine Related Gene Expression Signatures for Predicting the Overall Survival and Immune Responses of Patients with Colorectal Cancer

m<SUP>6</SUP>A Regulator-Based Methylation Modification Patterns Characterized by Distinct Tumor Microenvironment Immune Profiles in Rectal Cancer

The roles of m6A methylation in cervical cancer: functions, molecular mechanisms, and clinical applications

RNA methylation-related genes of m6A, m5C, and m1A predict prognosis and immunotherapy response in cervical cancer

Emerging Roles of RNA Methylation in Gastrointestinal Cancers

A comprehensive review of m6A research in cervical cancer

Comprehensive Analysis of Expression Regulation for RNA m6A Regulators With Clinical Significance in Human Cancers

m6A modification of RNA in cervical cancer: role and clinical perspectives

Identification of an Eight-M6a RNA Methylation Regulator Prognostic Signature of Uterine Corpus Endometrial Carcinoma Based on Bioinformatics Analysis

Clinicopathological and immunological characterization of RNA m 6 A methylation regulators in ovarian cancer.

The prognostic, immunological and single-cell features of m6A molecules in cervical cancer

Identification of the Relationship Between Single-Cell N6-methyladenosine Regulators and the Infiltrating Immune Cells in Esophageal Carcinoma.

Emerging Roles of m6A RNA Methylation Regulators in Gynecological Cancer